Roivant Sciences (NASDAQ:ROIV) PT Raised to $18.00 at The Goldman Sachs Group

Roivant Sciences (NASDAQ:ROIV - Get Free Report) had its price objective lifted by analysts at The Goldman Sachs Group from $16.00 to $18.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. The Goldman Sachs Group's price target indicates a potential upside of 56.39% from the company's current price.

Other research analysts have also recently issued research reports about the company. Truist Financial reissued a "buy" rating and issued a $23.00 target price on shares of Roivant Sciences in a research note on Monday, March 25th. Piper Sandler began coverage on shares of Roivant Sciences in a research report on Friday, January 5th. They set an "overweight" rating and a $20.00 price target for the company. HC Wainwright upped their price target on shares of Roivant Sciences from $17.00 to $18.00 and gave the company a "buy" rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft upped their price target on shares of Roivant Sciences from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Wolfe Research began coverage on shares of Roivant Sciences in a research report on Thursday, February 15th. They set an "outperform" rating and a $17.00 price target for the company. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $16.90.

Roivant Sciences Price Performance

ROIV traded up $0.59 during trading on Wednesday, reaching $11.51. The stock had a trading volume of 21,727,908 shares, compared to its average volume of 7,223,655. The stock has a market cap of $9.28 billion, a PE ratio of 2.21 and a beta of 1.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 27.79 and a current ratio of 27.79. Roivant Sciences has a one year low of $6.97 and a one year high of $13.24. The business has a 50-day moving average of $10.78 and a 200-day moving average of $10.36.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.07. The business had revenue of $37.14 million for the quarter, compared to analysts' expectations of $30.72 million. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. As a group, equities research analysts anticipate that Roivant Sciences will post -1.36 EPS for the current fiscal year.

Insider Transactions at Roivant Sciences

In other news, COO Eric Venker sold 96,950 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the completion of the sale, the chief operating officer now directly owns 532,207 shares in the company, valued at $5,811,700.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors have recently bought and sold shares of ROIV. Dagco Inc. bought a new position in Roivant Sciences in the fourth quarter worth about $27,000. Citigroup Inc. increased its stake in shares of Roivant Sciences by 1,803.6% during the first quarter. Citigroup Inc. now owns 5,749 shares of the company's stock valued at $28,000 after purchasing an additional 5,447 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Roivant Sciences by 60,550.0% during the first quarter. Royal Bank of Canada now owns 6,065 shares of the company's stock valued at $30,000 after purchasing an additional 6,055 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Roivant Sciences during the fourth quarter valued at approximately $33,000. Finally, Headlands Technologies LLC bought a new position in shares of Roivant Sciences during the fourth quarter valued at approximately $36,000. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.